文献速递食管与纵隔外科

内镜黏膜切除时代的食管切除术结局

Esophagectomy Outcomes in the Endoscopic Mucosal Resection Era.
PubMed 文献 · Ann Thorac Surg · 2016-12-10

本研究回顾性分析10年间51例cT1食管腺癌患者接受EMR后行食管切除术的结局。根据EMR组织学风险评分,73%为淋巴结转移高风险,27%术后分期升高;中风险组5年生存率低于高风险组(54% vs 84%,p=0.04)。结论提示应频繁再分期和监测,EMR无法控制疾病时低门槛行食管切除术。

要点

  • cT1食管腺癌EMR后食管切除术围术期死亡4%,并发症43%。
  • EMR组织学风险评分中风险组5年生存率低于高风险组(54% vs 84%,p=0.04)。
  • EMR后27%患者术后分期升高,需频繁再分期和监测。

核心结论

  • cT1食管腺癌患者可分为EMR用于分期后行食管切除术和EMR治疗后食管切除术作为挽救手术两类。
  • 应避免后一类患者分期升高,推荐频繁再分期和监测以防止疾病进展未被发现。
  • EMR无法控制疾病时应考虑低门槛行食管切除术。

研究设计与样本

  • 回顾性研究,10年间共1092例食管切除术,其中51例因cT1食管腺癌行EMR后食管切除术。
  • 使用基于EMR组织学的风险评分工具预测淋巴结转移。

主要发现

  • EMR至食管切除术平均时间4个月(SD,8.0)。
  • 风险评分:低风险1例,中风险13例(25%),高风险37例(73%)。
  • 中风险组EMR至手术时间更长(9 vs 1.4个月,p=0.03),多次EMR患者更多(38% vs 11%,p=0.04)。
  • 术后并发症43%,死亡4%;肺炎6%(3/51),房颤8%(4/51),临床吻合口漏12%(6/51)。
  • 27%(14/51)术后分期升高;淋巴结转移在中风险组3/13(23%),高风险组7/37(19%)。

关键数值与推荐

  • 风险评分中风险组5年生存率54%,高风险组84%(p=0.04)。

临床怎么用

  • 对cT1食管腺癌EMR后患者应频繁再分期和监测。
  • EMR无法控制疾病时考虑低门槛行食管切除术。

局限性

  • 回顾性研究,样本量小(51例),单中心经验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endoscopic mucosal resection (EMR) and esophagectomy are treatment options for cT1 esophageal adenocarcinoma. Our aim was to study outcomes for patients undergoing EMR then esophagectomy. METHODS: We identified patients undergoing EMR and esophagectomy for cT1 esophageal adenocarcinoma over 10 years. EMR histology was used to predict nodal involvement with a risk-scoring tool. Patient demographics, surgical techniques, pathology, postoperative outcomes, and survival were recorded. RESULTS: Of 1,092 that esophagectomies were performed, 51 patients underwent EMR and esophagectomy for cT1 esophageal adenocarcinoma. The mean time between EMR and esophagectomy was 4 (SD,8.0) months. According to the risk-scoring tool based on EMR histology, 1 patient was low risk, 13 (25%) were at moderate risk, and 37 (73%) were at high risk for lymph node metastasis. The time between EMR and the surgical intervention was longer and more patients had multiple EMRs in the moderate-risk group (9 vs 1.4 months, p = 0.03) compared with the high-risk group (38% vs 11% patients, p = 0.04). Operative mortality was 4% and morbidity was 43%. Pneumonia occurred in 3 of 51 patients (6%), atrial fibrillation in 4 (8%), and clinical anastomotic leak in 6 (12%). Of the 51 patients, 14 (27%) were upstaged after esophagectomy. Nodal involvement was present in 3 of 13 moderate-risk patients (23%) and in 7 of 37 high-risk patients (19%). The 5-year survival was reduced in moderate-risk compared with high-risk patients (54% vs 84%, p = 0.04). CONCLUSIONS: Studying outcomes for cT1 esophageal adenocarcinoma is important. These patients can be divided into those undergoing EMR for staging before esophagectomy and those in whom esophagectomy is a salvage procedure after therapeutic EMRs. Care should be taken to avoid upstaging of patients in the latter group, and we recommend frequent restaging and surveillance to prevent undetected progression of disease. A low threshold for esophagectomy when EMR fails to control disease should be considered.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Dickinson KJ, Wang K, Zhang L, et al. Esophagectomy Outcomes in the Endoscopic Mucosal Resection Era. Ann Thorac Surg. 2016. PMID: 27964921. doi:10.1016/j.athoracsur.2016.08.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。